Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Strategy India

Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars

Eylea Biosimilar Option Exercised

  • Analysis

Executive Summary

Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.

You may also be interested in...



MGC And GlycoNex Kick Off Denosumab Trial In Japan

Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.

Sandoz Follows US Denosumab Filing With European Acceptance

Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.

Samsung Bioepis Reveals Ustekinumab Progress

Samsung Bioepis has reported positive Phase I data for its SB17 ustekinumab candidate, a proposed biosimilar to Stelara.

Table

View full table

Related Content

Generics Bulletin
Scrip
Generics Bulletin
Scrip
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Biosimilars Strategy India
Latest Headlines

Celltrion And Rani Partner For Oral Adalimumab

Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico

MGC And GlycoNex Kick Off Denosumab Trial In Japan

Neuraxpharm Brings In Greek Olanzapine Brand

See All
UsernamePublicRestriction

Register

GB151856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By